CheckMate914
Por um escritor misterioso
Descrição
Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments
Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments
Fine-Tuning the Wave of Innovation in RCC
Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade
Adjuvant Immunotherapy in Resected Renal Cell Carcinoma: Déjà vu or Progress?
Adjuvant Pembrolizumab After Nephrectomy in Renal Cell Carcinoma: Embracing the Promises and Acknowledging the Uncertainties
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States - Clinical Genitourinary Cancer
Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro
ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial
Adjuvant immunotherapy does not improve DFS in renal cancer
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - The Lancet
Enrique Grande on X: 🔘 On @TheLancet - Assessing the efficacy and safety of adjuvant nivolumab + ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914) #immunotherapy #kidneycancer
